Publications
Fiber density and matrix stiffness modulate distinct cell migration modes in a 3D stroma mimetic composite hydrogel
Hiraki, HL,
Matera, DL,
Wang, WY,
Prabhu, ES,
Zhang, Z,
Midekssa, F,
Argento, AE,
Buschhaus, JM,
Humphries, BA,
Luker, GD,
Pena-Francesch, A,
Baker, BM,
Acta Biomater, 2023 Jun; DOI:10.1016/j.actbio.2022.09.043 Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.
Tawbi, HA,
Hodi, FS,
Lipson, EJ,
Schadendorf, D,
Ascierto, PA,
Matamala, L,
Gutiérrez, EC,
Rutkowski, P,
Gogas, H,
Lao, CD,
Janoski De Menezes, J,
Dalle, S,
Arance, AM,
Grob, J-J,
Ratto, B,
Rodriguez, S,
Xu, Y,
Dolfi, S,
Long, GV,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.9502 Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067.
Hodi, FS,
Chiarion-Sileni, V,
Gonzalez, R,
Grob, J-J,
Rutkowski, P,
Lao, CD,
Cowey, CL,
Schadendorf, D,
Wagstaff, J,
Dummer, R,
Queirolo, P,
Smylie, M,
Butler, MO,
Hill, AG,
Marquez-Rodas, I,
Ritchings, C,
Sakkal, LA,
Wang, P,
Wolchok, JD,
Larkin, J,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.9542 Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic merkel cell carcinoma (MCC) (CheckMate 358).
Bhatia, S,
Topalian, SL,
Sharfman, WH,
Meyer, T,
Lao, CD,
Fariñas-Madrid, L,
Devriese, LA,
Aljumaily, R,
Ferris, RL,
Honma, Y,
Khan, TA,
Srirangam, A,
Garnett-Benson, C,
Lee, M,
Nghiem, P,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.9506 Imaging of pediatric neuroblastoma: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper
Lai, HA,
Sharp, SE,
Bhatia, A,
Dietz, KR,
McCarville, B,
Rajderkar, D,
Servaes, S,
Shulkin, BL,
Singh, S,
Trout, AT,
Watal, P,
Parisi, MT,
Pediatr Blood Cancer, 2023 Jun; DOI:10.1002/pbc.29974 Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).
Schadendorf, D,
Tawbi, HA,
Lipson, EJ,
Hodi, FS,
Ascierto, PA,
Larkin, J,
Lao, CD,
Grob, J-J,
Ejzykowicz, F,
Moshyk, A,
Horton, VG,
Zhou, J,
Xin, Y,
Palaia, J,
McDonald, L,
Keidel, S,
Salvatore, A,
Sakkal, LA,
Long, GV,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.9552 Venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer.
McLaughlin, HD,
Straubhar, AM,
Rolston, A,
McCool, K,
Brackmann, M,
Siedel, JH,
McLean, K,
Reynolds, RK,
Uppal, S,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.5552 Genetic testing outcomes and pathogenic germline mutation prevalence in renal cell carcinoma.
Nguyen, CB,
Knaus, C,
Accardo, M-L,
Koeppe, E,
Alva, AS,
Else, T,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.10601 Correlation of unobserved incidence of cancer in earlier stages with the observed incidence.
Chhatwal, J,
ElHabr, A,
Tyson, C,
Merdan, S,
Cao, X,
Raoof, S,
Ozbay, AB,
Fendrick, AM,
Limburg, PJ,
Beer, TM,
Deshmukh, A,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.10634 High-grade B-cell lymphoma with concurrent MYC rearrangement and 11q aberrations: clinicopathologic, cytogenetic, and molecular characterization of 4 cases
Shestakova, A,
Shao, L,
Smith, LB,
Ryan, R,
Bedell, V,
Murata-Collins, J,
Zhang, W,
Perry, AM,
Song, JY,
Hum Pathol, 2023 Jun; DOI:10.1016/j.humpath.2023.03.013 Colorectal cancer screening with blood-based tests: Estimated impact of a 1-, 2-, or 3-year screening interval compared with annual FIT and triennial mt-sDNA strategies.
Fendrick, AM,
Kisiel, JB,
Ebner, DW,
Ozbay, AB,
Vahdat, V,
Estes, C,
Limburg, PJ,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.10580 Estimated value-based pricing for blood-based colorectal cancer screening test versus multi-target stool DNA test.
Kisiel, JB,
Fendrick, AM,
Borah, BJ,
Ebner, DW,
Ozbay, AB,
Vahdat, V,
Estes, C,
Limburg, PJ,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.e18911 Clinical efficacy analysis of patients (pts) with HER-2 expressing metastatic urothelial carcinoma (mUC) treated with enfortumab vedotin (EV).
Jiang, C,
Alhalabi, O,
Haro-Silerio, J,
Qiao, W,
Shah, AY,
Siefker-Radtke, AO,
Gao, J,
Goswami, S,
Alva, AS,
Koshkin, VS,
Guo, C,
Campbell, MT,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.e16618 Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
Jindal, T,
Zhang, L,
Jiang, C,
Kilari, D,
Alhalabi, O,
Nizam, A,
Basu, A,
Bilen, MA,
Zakharia, Y,
Milowsky, MI,
Shah, S,
Hoimes, CJ,
Davis, NB,
Gupta, S,
Emamekhoo, H,
Grivas, P,
Bellmunt, J,
Campbell, MT,
Alva, AS,
Koshkin, VS,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.4573 Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
Jindal, T,
Jiang, C,
Alhalabi, O,
Bakaloudi, DR,
Talukder, R,
Davidsohn, M,
Nizam, A,
Taylor, AK,
Nguyen, CB,
Kilari, D,
Pywell, C,
Davis, NB,
Emamekhoo, H,
Sonpavde, GP,
Gupta, S,
Bellmunt, J,
Grivas, P,
Campbell, MT,
Alva, AS,
Koshkin, VS,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.4572 Variations in the approach to lung metastases in osteosarcoma among pediatric and adult patients.
Wytiaz, VA,
Rice, J,
Rao, R,
Schuetze, S,
Chang, AC,
Reddy, RM,
Angeles, CV,
Chugh, R,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.11528 SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.
Lerner, SP,
Tangen, C,
Svatek, RS,
Daneshmand, S,
Pohar, KS,
Skinner, EC,
Schuckman, AK,
Sagalowsky, AI,
Smith, ND,
Kamat, AM,
Kassouf, W,
Plets, M,
Bangs, R,
Koppie, TM,
Alva, AS,
La Rosa, FG,
Pal, SK,
Kibel, AS,
Canter, D,
Thompson, IM,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.4508 Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials.
Unger, JM,
Schenkel, C,
Stires, H,
Levit, L,
Stewart, M,
McKelvey, BA,
Canin, B,
Dressler, EVM,
Flaherty, K,
Fredette, P,
Jones, L,
McCann, M,
Miller, T,
Onitilo, AA,
Palmieri, FM,
Patel, T,
Paul, R,
Smith, GL,
Bruinooge, SS,
Alva, AS,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.1565 Role of HLA-DRB4 as a biomarker for endocrine toxicity and survival outcomes after immunotherapy in metastatic non-small cell lung cancer.
Jiang, C,
Ravishankar, S,
Zhao, L,
Green, M,
Towlerton, A,
Scott, A,
Raghavan, M,
Cusick, M,
Warren, EH,
Ramnath, N,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.e21005 Anal Carcinoma, Version 2.2023
Benson, AB,
Venook, AP,
Al-Hawary, MM,
Azad, N,
Chen, Y-J,
Ciombor, KK,
Cohen, S,
Cooper, HS,
Deming, D,
Garrido-Laguna, I,
Grem, JL,
Hecht, JR,
Hoffe, S,
Hubbard, J,
Hunt, S,
Hussan, H,
Jeck, W,
Johung, KL,
Joseph, N,
Kirilcuk, N,
Krishnamurthi, S,
Maratt, J,
Messersmith, WA,
Meyerhardt, J,
Miller, ED,
Mulcahy, MF,
Nurkin, S,
Overman, MJ,
Parikh, A,
Patel, H,
Pedersen, K,
Saltz, L,
Schneider, C,
Shibata, D,
Skibber, JM,
Sofocleous, CT,
Stotsky-Himelfarb, E,
Tavakkoli, A,
Willett, CG,
Williams, G,
Algieri, F,
Gurski, L,
Stehman, K,
J Natl Compr Canc Netw, 2023 Jun; DOI:10.6004/jnccn.2023.0030 The role of tunneling nanotubes during early stages of HIV infection and reactivation: implications in HIV cure.
Valdebenito, S,
Ono, A,
Rong, L,
Eugenin, EA,
NeuroImmune Pharm Ther, 2023 Jun; DOI:10.1515/nipt-2022-0015 Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC).
Talukder, R,
Bakaloudi, DR,
Lin, GI,
Enright, T,
Leary, JB,
Makrakis, D,
Tripathi, N,
Agarwal, N,
Jindal, T,
Koshkin, VS,
Brown, JR,
Johnson, J,
Zakharia, Y,
Park, JJ,
Alva, AS,
Morales Barrera, R,
Drakaki, A,
Barata, PC,
Khaki, AR,
Grivas, P,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.4574 A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non–small-cell lung cancer (NSCLC).
Wells, L,
Qin, A,
Rice, J,
Gadgeel, SM,
Schneider, BJ,
Ramnath, N,
Zhao, L,
Kalemkerian, GP,
Journal of Clinical Oncology, 2023 Jun; DOI:10.1200/jco.2023.41.16_suppl.e21062 The Role of Surgery in Oligometastatic Retroperitoneal Sarcoma
Janes, LA,
Angeles, CV,
Curr Oncol, 2023 May; DOI:10.3390/curroncol30060398 Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer
Jiang, C,
Zhao, L,
Green, M,
Ravishankar, S,
Towlerton, A,
Scott, A,
Raghavan, M,
Cusick, M,
Warren, E,
Ramnath, N,
2023 May; DOI:10.21203/rs.3.rs-2929223/v1 